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Objective. The purpose of the present study was to determine the prevalence and incidence of virological
triple drug–class failure (TCF) and to summarize the clinical outcome for patients who started receiving highly
active antiretroviral therapy (HAART).
Methods. The present study is an observational longitudinal study of 3496 treatment-experienced (TE) and
treatment-naive (TN) patients monitored from the time they started receiving HAART (baseline) until TCF occurred
(as determined on the basis of viral loads), until AIDS was newly diagnosed, or until death.
Results. Four hundred forty-five patients (12.7%) had TCF; 370 (16.6%) of 2230 patients were TE, and 75
(5.9%) of 1266 patients were TN. At 6 years after starting HAART, 21.4% of TE and 11.2% of TN patients had
TCF ( ). The prevalence of TCF at or after 2002 was 15.5% in TE patients and 4.8% in TN patients. TNP ! .0001
patients had a 32% annual increase in the incidence of TCF (95% confidence interval [CI], 14%–54%; P !
); at 5 years after starting HAART, the rate was comparable for TE and TN patients (3.3 and 3.4 cases/100.0001
person-years of follow-up [PYFU], respectively). The incidence of new cases of AIDS or death was 2.7 cases/100
PYFU in patients who did not experience TCF and 5.0 cases/100 PYFU in patients who did experience TCF, an
estimated 36% increase with each category of TCF (95% CI, 19%–56%; ).P ! .0001
Conclusion. The prevalence of TCF was low after patients started receiving HAART, particularly among TN
patients. Despite the influx of patients who had started receiving HAART more recently, the prevalence of TCF
increased over calendar time. Patients with TCF had a higher incidence of newly diagnosed AIDS or death. Treatment
of patients with TCF deserves further investigation.
One of the goals of highly active antiretroviral therapy
(HAART) is to reduce the viral load to below the limit
of detection, which reduces the chances of further viral
evolution in response to therapeutic selection pressures.
Despite an initial good response to HAART, the viral
load may rebound in some patients. This phenomenon
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might be related to potentially serious adverse events,
the emergence of drug-resistant viruses, and the diffi-
culties of maintaining long-term adherence [1, 2]. Pa-
tients with rebounding viral load are typically switched
to a second-line or salvage regimen, in which the re-
sponse is usually poorer than that elicited when patients
first start HAART [3–6]. Such salvage regimens often
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contain a different class of antiretrovirals, so an initial protease
inhibitor (PI)–containing HAART regimen may be switched to
a nonnucleoside reverse-transcriptase inhibitor (NNRTI)–con-
taining HAART regimen or vice versa. Once patients have ex-
perienced virological failure of the 3 main classes of antiret-
rovirals (i.e., triple drug–class failure [TCF]), their treatment
options are limited because of cross-resistance; for such pa-
tients, it is usually not possible to keep the viral load at suf-
ficiently low levels, and this may lead to decreasing CD4 cell
counts and clinical disease progression [7, 8]. Although there
is considerable evidence from both observational studies and
clinical trials of the response to both first-line and second-line
HAART regimens [9–11], relatively little is known about the
time to or incidence of TCF. The aims of the present study
were, therefore, to describe the time to and prevalence and
incidence of TCF among 3496 patients from across Europe
who started receiving HAART and to summarize the clinical
outcome in these patients.
PATIENTS AND METHODS
Patients. The EuroSIDA study is a prospective, European-
based study of patients with HIV-1 infection in 72 centers in
Europe, Israel, and Argentina. Details of the study have been
published elsewhere [12]. In brief, centers provided data on
consecutive patients who were seen in the outpatient clinic,
from 2 May 1994 until a predefined number of patients was
enrolled from each center. This cohort of 3115 patients was
defined as the EuroSIDA I cohort. A second cohort (EuroSIDA
II cohort; 1365 patients) was enrolled beginning in December
1995, a third cohort (EuroSIDA III cohort; 2839 patients) was
enrolled beginning in April 1997, a fourth cohort (EuroSIDA
IV cohort; 1225 patients) was enrolled beginning in April 1999,
and a fifth cohort (EuroSIDA V cohort; 1258 patients) was
enrolled beginning in September 2001. At recruitment, in ad-
dition to demographic and clinical information, a complete an-
tiretroviral history was obtained, together with the 4 most recent
CD4 cell counts and viral load measurements. At each follow-
up visit, details on all CD4 cell counts measured since the last
follow-up visit and viral load measurements were collected, as
was the date of starting and stopping each antiretroviral drug
and information on the use of drugs for prophylaxis against
opportunistic infections. The latest follow-up visit was in De-
cember 2003. Members of the coordinating office visited all cen-
ters to ensure that patient selection was performed correctly and
that accurate data were provided, by checking the information
provided against case notes for a proportion of patients.
HAART was defined as a minimum of 3 antiretroviral drugs,
of which at least 1 was a PI, an NNRTI, or abacavir. All patients
receiving HAART for the first time were eligible for inclusion.
Patients who had previously taken a PI or an NNRTI that was
not included in a HAART regimen were excluded. The baseline
date was taken as the date of starting HAART. Patients for
whom a CD4 cell count or viral load was not measured during
the 6 months before baseline were excluded, as were patients
with no prospective follow-up. Patients who started receiving
HAART before recruitment to EuroSIDA were included only
if they had a minimum of 2 viral loads measured in each year
before recruitment, to ensure that patients had not experienced
TCF before prospective follow-up began.
Virological failure of a drug class was defined as it was for
the Pursuing Later Treatment Options (PLATO) collaborative
study [7]. In brief, virological failure of a drug class was defined
as having occurred when all recorded viral loads were 11000
HIV RNA copies/mL for a total of 14 months after starting
the drug class while still receiving the same drug class. Failure
of any drug class could occur when it was used as monotherapy
or as a component of dual therapy, triple therapy, or a more
intensive regimen, if viral loads were 11000 copies/mL for 7
months while receiving the drug. Patients were classified as
having experienced TCF on the first date that therapy with
nucleosides, PIs, and NNRTIs failed. An alternative definition
of TCF was also analyzed (“other”), defined as failure of any
drug class after 14 months of receiving the drug class and on
the basis of a single viral load 11000 HIV RNA copies/mL.
Statistical methods. The prevalence of TCF at each time
point was defined as the proportion of patients with TCF up
to that date divided by the total number of patients being
followed up at that date. Patients were followed-up to the date
of their last viral load measurement. The incidence of TCF was
defined as the number of patients with TCF divided by the
person-years of follow-up (PYFU) and was stratified according
to the time since starting HAART and according to whether
patients were treatment experienced (TE) or treatment naive
(TN). Patient follow-up was measured from the date of starting
HAART (baseline) until the date of TCF. Patients who had not
experienced TCF were censored at the date of their last viral
load measurement. Trends over time were tested by use of
Poisson regression.
The time from starting HAART to TCF was analyzed by use
of Kaplan-Meier survival curves. The factors associated with
TCF were determined by use of Cox proportional hazards mod-
els. All Cox models were stratified by center and were per-
formed separately for TN and TE patients. Variables in uni-
variate analyses included sex, exposure group, race, hepatitis B
and C status, prior AIDS diagnosis, age, CD4 cell count, viral
load, and the availability of a resistance test before starting
HAART. A resistance test may have been obtained by the clinic
and reported to the coordinating center, or it may have been
performed by one of the central laboratories on a stored serum
sample as part of any one of a number of ongoing resistance
studies. Treatment variables included HAART regimen started,
date of starting antiretroviral therapy, and the number of an-
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Table 1. Characteristics of 3496 patients at risk of triple drug–class failure.
Characteristic TE patients TN patients Pa
Sex
Male 1724 (77.3) 999 (78.9) .27
Female 506 (22.7) 267 (21.1)
Exposure group
Homosexual 1015 (45.5) 594 (46.9) .15
IDU 497 (22.3) 242 (19.1)
Heterosexual 556 (24.9) 326 (25.8)
Other 162 (7.3) 104 (8.2)
Region
South/Argentina 682 (30.6) 265 (20.9) !.0001
Central 673 (30.2) 321 (25.4)
North 805 (36.1) 446 (35.2)
East 70 (3.1) 234 (18.5)
Ethnic origin
White 1866 (83.7) 1092 (86.3) .042
Other 364 (16.3) 174 (13.7)
HAART regimen
Single PI 1710 (76.7) 782 (61.8) !.0001
Boosted PI 124 (5.6) 117 (9.2)
Single NNRTI 328 (14.7) 312 (24.6)
Triple nucleoside 46 (2.1) 34 (2.7)
Other 22 (1.0) 21 (1.7)
Prior AIDS 546 (24.5) 257 (20.3) .0047
Resistance test
Before HAART 231 (10.4) 289 (22.8) !.0001
CD4 cell count, median (IQR), cells/mm3 220 (115–341) 231 (103–346) .0066
CD4 cell count nadir, median (IQR), cells/mm3 150 (63–230) 197 (92–304) !.0001
Viral load, median (IQR), HIV RNA copies/mL 4.18 (3.38–4.86) 4.92 (4.36–5.40) !.0001
Peak viral load, median (IQR), HIV RNA copies/mL 4.58 (3.97–5.15) 5.04 (4.56–5.49) !.0001
Age, median (IQR), years 37.6 (33.3–45.0) 36.0 (30.8–43.3) !.0001
Time started receiving HAART, median (IQR) Jun 1997 (Jan 1997–May 1998) Jun 1998 (May 1997–Aug 2000) !.0001
Total 2230 (63.8) 1266 (36.2) …
NOTE. Data are no. (%) of patients, except where noted. HAART, highly active antiretroviral therapy; IDU, injection drug use; IQR, interquartile range, NNRTI,
nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; TE, treatment experienced; TN, treatment naive.
a P values were calculated by use of the x2 test, for categorical variables, and the Wilcoxon test, for continuous variables.
tiretrovirals patients were taking at baseline. CD4 cell count
and viral load were included as continuous variables. In TE
patients, the additional variables considered included time since
starting antiretrovirals, the cumulative number of nucleosides
ever taken, the number of new (i.e., never previously taken)
nucleosides started with HAART, and what prior treatment
strategy patients had taken (monotherapy, dual therapy, or
both). A further Cox model that redefined the baseline date to
be 1 January 1987 was constructed, and patient follow-up was
left-truncated until the date of starting HAART. This analysis
allowed changes in the rate of TCF over time since starting
HAART to be formally tested after adjustment for the other
factors related to TCF. All analyses were repeated using the
alternative definition of TCF.
The incidence of new AIDS cases and death was calculated
after stratification by the number of drug classes that failed and
CD4 cell count (50, 51–200, and 1200 cells/mm3). Current (or
time-updated) values for both CD4 cell count and number of
drug classes failed were used. Failure of 1 or 2 classes of drugs
were combined because of the small number of PYFU or events
that occurred among patients for whom a single class of drugs
failed. Follow-up was from baseline to a new clinical AIDS-
defining illness or death (recurrence of an AIDS diagnosis or a
CD4 cell count !200 cells/mm3 were not counted as events).
All analyses were performed by use of SAS (version 8.2; SAS
Institute). All tests of significance were 2-sided.
RESULTS
Characteristics of the patients. Of 9802 patients enrolled in
EuroSIDA, 3939 had not started receiving HAART, and 2187
had no CD4 cell count or viral load data available for the 6
months before baseline. One hundred eighty patients were ex-
cluded because they had !2 viral loads/year measured before
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Figure 1. Prevalence of triple drug–class failure at 1 January over calendar time. HAART, highly active antiretroviral therapy.
Figure 2. Time to triple drug–class failure. HAART, highly active antiretroviral therapy.
recruitment to EuroSIDA; thus, 3496 patients satisfied the in-
clusion criteria (table 1). The majority of patients were TE
(np2230; 63.8%). TE patients had lower median CD4 cell
counts at the start of HAART ( ), lower viral loadsPp .0066
( ), and tended to have started receiving HAART at anP ! .0001
earlier time point ( ). For both TE and TN patients,P ! .0001
CD4 cell count and viral load at baseline was measured a me-
dian of 0 months before baseline (interquartile range [IQR],
0–1 months). During follow-up, there were a median of 16
viral load measurements/TE patient (IQR, 9–22 viral load mea-
surements) and 13 viral load measurements/TN patient (IQR,
8–20 viral load measurements), at a median interval of 3
months for both groups (IQR, 2–4 months). There were 9542
PYFU for TE patients and 4726 PYFU for TN patients.
TE patients started receiving antiretrovirals a median of 34
months before HAART (IQR, 15–59 months). A large pro-
portion of TE patients (58.0%; 1294 patients) had received both
monotherapy and dual therapy. The median number of anti-
retrovirals to which patients had been exposed before baseline
was 3 (IQR, 2–3 antiretrovirals). Almost half the patients start-
ing HAART did not start any new nucleosides (i.e., nucleosides
to which they had never previously been exposed) at baseline
(1059 patients; 47.5%), whereas 695 patients (31.2%) started
receiving 1 new nucleoside, and 476 patients (21.3%) started
receiving 2 new nucleosides.
Prevalence and incidence of TCF over time. During fol-
low-up, more than half of the patients who started receiving
HAART were exposed to 3 classes of antiretrovirals (1816 pa-
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Figure 3. Incidence of triple drug–class failure and time receiving highly active antiretroviral therapy (HAART). PYFU, person-years of follow-up.
tients; 51.9%). In total, 445 patients (12.7%) experienced TCF
after baseline; of these, 370 (16.6%) of 2230 were TE, and 75
(5.9%) of 1266 were TN. Figure 1 shows the prevalence of TCF
over time among patients who continued to be followed up.
During 1997, the prevalence of TCF was 0 for both TE and
TN patients; by 1999, the prevalence had increased to 3.4% for
TE patients and 1.7% for TN patients; and, at or after 2002,
the prevalence had increased to 16.1% for TE patients and 5.5%
for TN patients.
Time to and incidence of TCF. Figure 2 shows the time from
baseline to TCF. At 6 years after baseline, 21.4% (95% confidence
interval [CI], 19.3%–23.5%) of TE patients and 11.2% (95% CI,
8.4%–14.0%) of TN patients ( , log-rank test) were es-P ! .0001
timated to have TCF. The overall incidence of TCF was 1.6 cases/
100 PYFU (95% CI, 1.2–2.0 cases/100 PYFU) and 3.9 cases/100
PYFU (95% CI, 3.5–4.3 cases/100 PYFU) in TN and TE patients,
respectively. Figure 3 shows the incidence of TCF according to
time since baseline. Among TN patients, there was an increase
in the incidence of TCF with increasing time from baseline, from
1.0 cases/100 PYFU (95% CI, 0.6–1.4 cases/100 PYFU) during
the first 2 years after baseline to 3.3 cases/100 PYFU (95% CI,
1.8–5.7 cases/100 PYFU) at or after 5 years from baseline (32%
increase/year; 95% CI, 14%–54% increase/year; , Pois-P ! .0001
son regression), approaching the rate seen in TE patients treated
for the same period of time (3.4 cases/100 PYFU; 95% CI, 2.3–
4.5 cases/100 PYFU).
Is the rate of TCF increasing over time since starting
HAART? Given the pattern of TCF seen in figure 3, a con-
tinuous variable was used to model the time since baseline for
TN patients, whereas a categorical variable was fitted for TE
patients, with 2–3 years as the reference category. Among TN
patients, after adjustment for CD4 cell count and viral load at
baseline, there was a 43% increased risk of TCF with each extra
year since baseline (95% CI, 27%–62%; ). In TE pa-P ! .0001
tients, after adjustment for CD4 cell count and viral load at
baseline, the number of new nucleosides started, and the total
cumulative exposure to nucleosides before HAART, patients
had a 71% decreased risk of TCF during the first 2 years after
baseline (95% CI, 58%–80%; ), compared with theP ! .0001
risk at 2–3 years after baseline. After this time, there were no
significant differences in the risk of TCF with increasing time
from baseline. Similar results were seen when the first 2 years
of follow-up after baseline (when there were few TCFs) were
excluded from the analysis.
Factors associated with TCF. Table 2 shows the univariate
and multivariate factors associated with TCF in TN and TE
patients. Both CD4 cell count and viral load were included as
continuous variables. For TN patients, there was no statistically
significant relationship between the year that HAART was
started, exposure group, hepatitis B or C status, CD4 cell count
at baseline, availability of a resistance test before baseline, and
risk of TCF in multivariate analyses. The only factor associated
with TCF was a higher viral load, with a 55% increased risk
of TCF per log increase in viral load. For TE patients, the total
number of antiretrovirals taken before baseline, the number of
new drugs started, and regimens taken before baseline were
also included in multivariate analyses. There was no statistical-
ly significant relationship between the year that HAART was
started, the number of nucleosides received before HAART,
prior drug regimen, the availability of a resistance test before
baseline, and risk of TCF in multivariate analyses. After ad-
justment, patients with a higher viral load at baseline had a
41% increased risk of TCF per log increase in viral load, whereas
patients with a higher CD4 cell count at baseline had an 8%
reduced risk of TCF per 50% higher CD4 cell count. In ad-
dition, injection drug users had a 46% increased risk of TCF,
and patients who started receiving 2 new nucleosides at baseline
had a 32% reduced risk of TCF.
Changing the definition of TCF. The analyses were re-
peated using the alternative definition of TCF, which, among
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Table 2. Factors associated with triple drug–class failure.
Group of patients, factor
Univariate analysis Multivariate analysis
RH (95% CI) P RH (95% CI) P
Treatment naive
Prior AIDS 2.11 (1.25–3.58) .0055 1.47 (0.82–2.65) .20
IDU 1.12 (0.54–2.53) .76 1.24 (0.52–2.98) .63
Hepatitis B positive 0.80 (0.24–2.69) .72 1.00 (0.29–3.50) .99
Hepatitis C positive 0.98 (0.55–1.77) .95 0.48 (0.14–1.63) .24
Date started receiving HAART per calendar year later 0.72 (0.53–0.99) .041 0.80 (0.59–1.09) .16
CD4 cell count at start of HAART 50% higher 0.80 (0.70–0.91) .0006 0.89 (0.76–1.03) .12
Viral load at start of HAART log higher 1.81 (1.31–2.51) .0003 1.55 (1.10–2.16) .011
Resistance test before HAART 0.64 (0.29–1.39) .26 0.87 (0.39–1.98) .75
Treatment experienced
No. of new nucleosides started at HAARTa
1 0.88 (0.69–1.12) .30 0.95 (0.73–1.24) .70
2 0.58 (0.42–0.80) .0008 0.68 (0.4– 0.98) .040a
No. of nucleosides ever taken per extra 1 1.24 (1.11–1.39) .0002 1.12 (0.97–1.29) .12
Prior regimens takenb
Dual therapy 1.01 (0.62–1.63) .98 0.96 (0.58–1.59) .86
Monotherapy and dual therapy 1.50 (0.96–2.34) .079 1.18 (0.72–1.94) .50
Prior AIDS 1.58 (1.25–1.98) !.0001 1.17 (0.91–1.51) .21
IDU 1.57 (1.17–2.12) .0030 1.46 (1.00–2.12) .048
Hepatitis B positive 1.11 (0.73–1.69) .63 1.07 (0.70–1.65) .75
Hepatitis C positive 0.68 (0.50–0.93) .016 0.88 (0.60–1.30) .52
Date started receiving HAART per calendar year later 0.68 (0.58–0.79) !.0001 0.89 (0.76–1.05) .17
CD4 cell count at start of HAART 50% higher 0.83 (0.78–0.88) !.0001 0.92 (0.86– 0.9) .019
Viral load at start of HAART log higher 1.51 (1.35–1.69) !.0001 1.41 (1.25–1.59) !.0001
Resistance test before HAART 0.79 (0.51–1.22) .28 0.99 (0.63–1.54) .96
NOTE. CI, confidence interval; HAART, highly active antiretroviral therapy; IDU, injection drug use; RH, relative hazard.
a Compared with no new nucleosides.
b Compared with monotherapy.
TE patients, resulted in a prevalence of TCF that was consis-
tently higher than that calculated according to the PLATO def-
inition, reaching 29.1% at or after 2003. There was little dif-
ference in the prevalence of TCF in TN patients, which reached
6.4% at or after 2003. At 6 years after starting HAART, 35.5%
of TE patients were estimated to have TCF (95% CI, 36.1%–
40.9%), higher than the level found using the PLATO defini-
tion, whereas a very similar proportion of TE patients had TCF
(9.8% at 6 years; 95% CI, 7.4%–12.2%). The incidence of TCF
with time receiving HAART showed a similar pattern to that
shown in figure 3 for both TE and TN patients, but, once again,
the incidence of TCF was higher for TE patients when the
alternative definition of TCF was used than when the PLATO
definition was used. The factors related to TCF were highly
consistent when the other definition was used (data not shown).
Clinical outcome. There was an increase in the incidence
of new cases of AIDS and death with increasing numbers of
drug classes failed. The incidence of new AIDS cases and death
was 2.7 cases/100 PYFU (95% CI, 2.3–3.1 cases/100 PYFU) in
patients with no drug-class failure, 3.7 cases/100 PYFU in pa-
tients with 1–2 drug-class failures (95% CI, 3.3–4.1 cases/100
PYFU), and 5.0 cases/100 PYFU in patients with TCF (95%
CI, 3.7–6.3 cases/100 PYFU). There was an estimated 36% in-
creased incidence of new AIDS cases and death with each cat-
egory of drug-class failure (95% CI, 19%–56% increased in-
cidence; , Poisson regression). The increased incidenceP ! .0001
was particularly marked among patients with a current CD4
cell count 50 cells/mm3 (figure 4), for whom there was an
estimated 47% increased incidence of new AIDS cases and death
with category of drug-class failure (95% CI, 12%–93% in-
creased incidence; , Poisson regression). There was noPp .006
significant change among patients with current CD4 cell counts
of 51–200 cells/mm3 ( ), and an estimated 20% increasePp .70
per category of drug-class failure (95% CI, 0.99%–1.48% in-
crease; , Poisson regression) among those with CD4Pp .056
cell counts 1200 cells/mm3.
DISCUSSION
By 2003, 1 of 20 TN patients and 1 of 6 TE patients from the
EuroSIDA study who started receiving HAART experienced
TCF. The incidence of TCF was considerably lower among TN
patients but increased with increasing time since starting
HAART. The incidence of TCF among TE patients was stable
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Figure 4. No. of triple drug–class failures and incidence of AIDS or deaths after starting highly active antiretroviral therapy (HAART). PYFU, person-
years of follow-up.
after an initially low incidence during the first 2 years after
starting HAART. The World Health Organization projects that
3 million people with HIV in the developing world will be
receiving treatment by the end of 2005 [13]. Because the rate
of TCF in the developing world will probably be comparable
to that reported here, the number of patients with TCF world-
wide will continue to increase during the coming years, as the
population with extended exposure to HAART in the developed
world increases.
Six years after starting HAART, ∼20% of TE patients and
10% of TN patients were estimated to have TCF. In small,
detailed studies with extended follow-up, ∼30% of patients who
were initially TN experienced virological failure during their
first HAART regimen, 2–3 years after starting HAART [14, 15].
In larger observational studies, 20%–40% of patients experi-
enced virological failure during their first HAART regimen, on
the basis of an average of 2–3 years of follow-up [16, 17]. The
definition of virological failure differs between studies, as do
the patients included, but patients whose initial HAART reg-
imen failed usually change to a regimen containing a different
class of drug and are, therefore, at immediate risk of TCF,
according to the PLATO definition. Our estimates of TCF in
TN and TE patients 6 years after starting HAART appear to
be consistent with the above estimates, coupled with estimates
suggesting that a further 20%–50% of patients experience fail-
ure of second-line regimens [3–6].
Several studies have shown that TE patients have a poorer
virological response to HAART than do TN patients [18–20],
but, in general, there has been no difference in the risk of
clinical progression between TE and TN patients [21–23]. How-
ever, it may take years from TCF to clinical progression, and,
with extended follow-up, differences in clinical progression may
become apparent. To date, cross-resistance to antiretroviral clas-
ses has been irreversible; thus, the prevalence of patients living
with TCF will increase over time, both within a study popu-
lation such as EuroSIDA and within the population of patients
with HIV, as more patients are exposed to more drug classes.
For the individual, this may lead to a poorer prognosis and to
potential transmission of resistant virus to others [24]. For the
clinics, it may lead to increased costs due to more-intensive
diagnostic tests, the use of more-expensive drugs such as en-
furvirtide [25], and the use of more drugs in each regimen.
The incidence of TCF increased with more-extended expo-
sure to HAART among TN patients but remained fairly steady
among TE patients, after an initially low rate. The low rate of
TCF among TN patients during 2001 may be explained, in
part, by the comparatively high number of TN patients who
started receiving HAART during this time period, because pa-
tients who recently started receiving HAART were compara-
tively overrepresented. By 5 years after starting HAART, the
incidence of TCF in TN patients was similar to that in TE
patients, although the CIs around the estimate were wide. The
initially low and then steady rate of TCF in TE patients may
reflect that, during the first years after starting HAART, patients
with rapid TCF had more resistance and were least able to
adhere to the new regimens, or it may reflect differences in
early treatment guidelines [26]. Once such patients have TCF,
the remaining TE patients may experience TCF at a rate similar
to that seen in TN patients, and the curves will increase at the
same rate, with extended exposure to HAART.
The factors related to TCF in the present study were similar
to those related to failure of a first- or second-line regimen [5,
27–31]. TE patients and those who had a high viral load or
low CD4 cell count had an increased risk of TCF. Although a
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number of studies have shown a significant correlation between
drug resistance and virological response [32, 33], the role of
resistance testing remains unclear. We found no relationship
between the availability of a pre-HAART resistance test and
TCF. In patients with extensive prior treatment and multiple
treatment failures, the interpretation of resistance tests is dif-
ficult, and other factors, such as adherence, treatment history,
and toxicities, need to be taken into account [34–36].
We used a definition of TCF based on the PLATO definition,
which classifies failure as viral loads 11000 HIV RNA copies/
mL for 14 months while receiving each class of drug [7]. In
the present study, viral loads were measured, on average, every
3 months. We repeated our analysis using an alternative defi-
nition of TCF, and the results showed consistently higher rates
of TCF in TE patients. In general, however, the differences
between TN and TE patients remained the same, and similar
factors were related to TCF. Most randomized clinical trials
define virological failure on the basis of a viral load 150 HIV
RNA copies/mL. We believe that the PLATO definition rep-
resents a more conservative approach to virological failure, one
that may be used in the routine clinic setting, where there may
be less-frequent monitoring of patients, and maintenance on
a regimen with that keeps viremia at low levels. The PLATO
definition has been shown to have clinical relevance [7] and is
a measure of extensive drug exposure and virological failure
during therapy. It should be recognized that some failures may
be due to poor adherence and that a patient with TCF may
still respond to another drug within these classes.
We found a significant increase in the incidence of new cases
of AIDS and death with an increasing number of drug-class
failures. This trend was most pronounced among patients with
a current CD4 cell count of 50 cells/mm3. Although patients
with TCF have significantly higher rates of clinical disease, the
PLATO study demonstrated that, even among patients for
whom it was not possible to completely suppress viremia, the
risk of clinical progression remained low as long as the CD4
cell count was maintained at 1200 cells/mm3 [7]. Further, the
incidence of clinical progression was ∼5/100 PYFU, significant-
ly lower than the rate of disease progression seen in EuroSIDA
before 1998 [12].
There are several limitations of the present study that should
be noted. The results from clinical trials and observational stud-
ies have shown that adherence plays a role in virological failure
[15, 35, 37, 38], data we do not currently have. It is likely that
some patients may have TCF because of poor adherence and
thus would not have resistance. The future responses to therapy
for nonadherent patients could be different from those for
patients with TCF and resistance; sustained virological sup-
pression should be achievable if good adherence can be achieved
and maintained on future regimens. We had only a small se-
lected patient group with available resistance tests before start-
ing HAART, and further work is ongoing to collect resistance
data at baseline and at TCF. We used a definition of TCF based
on the PLATO study, but we performed several additional sen-
sitivity analyses. The results were highly consistent when we
changed the criteria for failure to 6 months with a viral load
11000 HIV RNA copies/mL, when we left-truncated the data
until prospective follow-up in the EuroSIDA study began, or
when we excluded patients who started receiving HAART be-
fore prospective follow-up. In addition, although nevirapine
became available in the middle of 1996, efavirenz was not wide-
ly used by EuroSIDA patients until 1998 [39]. A further sen-
sitivity analysis that included only patients who started receiving
HAART in 1998 or later showed similar results.
Further treatment options, such as mega-HAART regimens
or treatment interruptions [40–42], will be needed as the num-
ber of patients with TCF increases. The recent introduction of
fusion inhibitors, with which 20% of patients experienced viral
suppression after 48 weeks [43], is unlikely to significantly di-
minish the proportion of patients with virological failure of all
classes of antiretrovirals (i.e., 4 classes). Other treatment op-
tions, such as conserving drugs for future treatment options,
are currently being investigated in clinical trials. In the Strate-
gies for Management of Anti-Retroviral Therapy study, HAART
is used both periodically, to maintain the CD4 cell count at
1200 cells/mm3 in the drug-conservation arm, and at all time
points, to maximize viral suppression in the virological sup-
pression arm (http://www.smart-trial.org/).
In summary, although it is possible that further treatment
improvements over the next 5 years will make TCF less likely
than reported here, these results estimate TCF among a het-
erogeneous pan-European population where there are many
factors involved in decisions about which regimen to start and
the virological threshold required for treatment failure. Given
that patients with TCF experience higher rates of clinical pro-
gression, it seems important to optimize the first-line HAART
regimen to avoid virological failure. The long-term conse-
quences of TCF on the durability of HAART and on the re-
duction in clinical progression of disease and how best to man-
age this situation deserve further focus.
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